TECARTUS adverse reactions

Summary of adverse
reactions observed in ≥10%
of patients
treated with
TECARTUS in ZUMA-2
(N=82)

Adverse
Reactions

Any Grade (%)

Grade ≥3 (%)

Blood and Lymphatic System Disorders

Coagulopathy

Cardiac Disorders

10

2

Tachycardias

Bradycardias

Non-ventricular
arrhythmias

45

10

10

0

0

4

Gastrointestinal Disorders

Nausea

Constipation

Diarrhea

Abdominal pain

Oral pain

Vomiting

Dysphagia

35

29

28

17

16

13

10

1

0

5

0

0

0

2

General Disorders and
Administration Site Conditions

Fever

Fatigue

Chills

Edema

Pain

94

48

41

35

17

15

1

0

2

2

Immune System Disorders

Cytokine release
syndrome

Hypogammaglobulinemia

91
 

16

18
 

1

Infections and Infestations

Infections with
pathogen unspecified

Viral infections

Bacterial infections

43

 

18

13

24

 

4

6

Metabolism and Nutrition Disorders

Decreased appetite

26

0

Musculoskeletal and Connective
Tissue Disorders

Musculoskeletal pain

Motor dysfunction

37

17

2

4

Nervous System Disorders

Encephalopathy

Tremor

Headache

Aphasia

Dizziness

Neuropathy

51

38

35

20

18

13

24

2

1

7

6

2

Psychiatric Disorders

Insomnia

Delirium

Anxiety

21

18

16

0

5

0

Renal and Urinary Disorders

Renal insufficiency

Urine output decreased

18

11

9

1

Respiratory, Thoracic, and
Mediastinal Disorders

Hypoxia

Cough

Dyspnea

Pleural effusion

40

38

24

21

20

0

6

5

Skin and Subcutaneous
Tissue Disorders

Rash

22

4

Vascular Disorders

Hypotension

Hypertension

Thrombosis

57

18

17

27

11

4

Pinch to zoom

There were no Grade 5 neurologic events and there was one Grade 5 CRS in ZUMA-21,2

CRS=cytokine release syndrome.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Data on file. Kite Pharma, Inc; 2022.

Grade 3 or 4 lab abnormalities

Grade 3 or 4 laboratory
abnormalities occurring in
≥10% of
patients in
ZUMA-2 following
TECARTUS infusion (N=82)1

Grade 3 or 4 (%)

Leukopenia

95

Neutropenia

95

Lymphopenia

86

Thrombocytopenia

63

Anemia

55

Hypophosphatemia

30

Hypocalcemia

21

Blood uric acid increased

17

Hyponatremia

16

Aspartate aminotransferase increased

15

Alanine aminotransferase increased

15

Hypokalemia

10

Pinch to zoom

Prolonged cytopenias have occurred following treatment with TECARTUS1

  • Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and TECARTUS infusion
  • At Day 30, 55% of patients had unresolved Grade 3 or higher cytopenias
    • 38% with thrombocytopenia
    • 37% with neutropenia
    • 17% with anemia

No new safety signals were seen at a median potential follow-up of 35.6 months2,3

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Data on file. Kite Pharma, Inc; 2022. 3. Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555-567.